- Report
- May 2024
North America
From €1997EUR$2,095USD£1,707GBP
€3804EUR$3,990USD£3,250GBP
From €1997EUR$2,095USD£1,707GBP
€3804EUR$3,990USD£3,250GBP
- Report
- May 2024
Middle East
From €1997EUR$2,095USD£1,707GBP
€3804EUR$3,990USD£3,250GBP
- Report
- May 2024
Asia Pacific
From €1997EUR$2,095USD£1,707GBP
€3804EUR$3,990USD£3,250GBP
- Report
- March 2024
- 132 Pages
Global
From €906EUR$950USD£774GBP
- Report
- March 2024
- 132 Pages
Global
From €906EUR$950USD£774GBP
- Report
- March 2024
- 132 Pages
Global
From €906EUR$950USD£774GBP
- Report
- March 2024
- 132 Pages
Global
From €906EUR$950USD£774GBP
- Report
- November 2023
- 42 Pages
China
From €1044EUR$1,095USD£892GBP
- Book
- January 2016
- 472 Pages
- Book
- November 2013
- 744 Pages
The Biological Products for Human Use market is a subset of the biopharmaceutical industry, which focuses on the development and production of drugs and other treatments derived from living organisms. These products are used to treat a variety of medical conditions, ranging from cancer to autoimmune diseases. Biological products are typically produced using recombinant DNA technology, which involves the manipulation of genetic material to create new proteins or other molecules.
The Biological Products for Human Use market is highly regulated, with stringent safety and efficacy standards in place to ensure the safety of patients. Companies in this market must adhere to Good Manufacturing Practices (GMP) and other regulatory requirements in order to obtain approval from regulatory authorities.
Some of the major companies in the Biological Products for Human Use market include Amgen, Biogen, Celgene, Gilead Sciences, and Novartis. These companies are involved in the development and production of a wide range of biopharmaceuticals, including monoclonal antibodies, vaccines, and gene therapies. Show Less Read more